October 28, 2019
Mitsubishi Tanabe Pharma said on October 25 that it is raising its half-year earnings guidance for April-September thanks to strong performances from key products in Japan including the Crohn’s disease treatment Stelara (ustekinumab). For the first half of FY2019, the...read more